A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
Active, not recruiting · Phase 2 · NCT05690386
Conditions: Turner Syndrome
At a glance
- Research payments reported, 2025
- $446,356
- U.S. investigators named
- 17
- Sites paid
- 17
- Planned or actual enrollment
- 48
About the trial
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Tested
- Lonapegsomatropin (biological), Somatropin (drug)
- Dates
- Started 2023-02-15; completion 2027-12
- Results posted
- Not yet
A 104 week dose finding open label trial followed by an optional 78 week open label extension of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus daily somatropin product in prepubertal individuals with Turner syndrome. Approximately 48 individuals (12 individuals per arm) will be randomized to receive one of three doses of lonapegsomatropin or a daily injection of somatropin. This is a trial that will be conducted in the United States.
From ClinicalTrials.gov, last updated 2026-05-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ascendis Pharma Endocrinology Inc reported $446,356 in research payments for this study in 2025 (264 payments).
Products named: Skytrofa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Karen O. Klein, M.D. Pediatric Endocrinology · San Diego, CA
- Diane E. Stafford, M.D. Pediatric Endocrinology · Palo Alto, CA
- Shanlee M. Davis, M.D. Pediatric Emergency Medicine · Aurora, CO
- Mauri Carakushansky, MD Pediatric Endocrinology · Orlando, FL
- Supamit Ukarapong, M.D. Pediatric Endocrinology · St Petersburg, FL
- Doris Fadoju, MD Pediatric Endocrinology · Atlanta, GA
- Joshua M. Smith, M.D. Pediatric Endocrinology · Idaho Falls, ID
- Reema L. Habiby, M.D. Pediatric Endocrinology · Chicago, IL
- Benjamin U. Nwosu, M.D. Pediatric Endocrinology · Worcester, MA
- Mary J. Abuzzahab, MD Pediatric Endocrinology · Saint Paul, MN
- Jennifer R. Law, M.D. Pediatric Endocrinology · Chapel Hill, NC
- Iris Gutmark-little, M.D. Pediatric Endocrinology · Cincinnati, OH
- Jeanie Tryggestad, MD Pediatrics · Oklahoma City, OK
- Kathryn A. Woods, MD Pediatric Endocrinology · Portland, OR
- Hector M. Granados, MD Pediatric Endocrinology · El Paso, TX
- Paul S. Thornton, MD Pediatric Endocrinology · Fort Worth, TX
- Patricia Y. Fechner, MD Pediatric Endocrinology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Children's Hospital Colorado, CO $243,464
- The Regents of the University of California $59,696
- Children's Healthcare of Atlanta, Inc. $22,440
- Ann & Robert H Lurie Childrens Hospital of Chicago, IL $19,065
- All Children's Research Institute, Inc. $12,418
- Childrens Health Care $11,407
- Seattle Children's Hospital, WA $11,129
- Board of Regents of the University of Oklahoma Health Sciences Center $10,988
- Ohsu Hospital and Clinics, OR $10,815
- Nemours Childrens Hospital, Florida, FL $10,654
- Cincinnati Children's Hospital Medical Center, OH $7,419
- The Board of Trustees of the Leland Stanford Junior Unv. $7,383
- Medresearch Inc $5,860
- Cook Childrens Medical Center, TX $5,095
- University of North Carolina at Chapel Hill $4,186
- The Feinstein Institutes for Medical Research $3,034
- Rocky Mountain Clinical Research, LLC $1,304
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.